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Myeloid-lineage cells accomplish a myriad of homeostatic tasks including the recognition of pathogens, regulation
of the inflammatory milieu, and mediation of tissue repair and regeneration. The innate immune receptor and its
adaptor protein—triggering receptor expressed on myeloid cells 2 (TREM2) and DNAX-activating protein of 12 kDa
(DAP12)—possess the ability to modulate critical cellular functions via crosstalk with diverse signaling pathways. As
such, mutations in TREM2 and DAP12 have been found to be associated with a range of disease phenotypes. In
particular, mutations in TREM2 increase the risk for Alzheimer’s disease and other neurodegenerative disorders. The
leading hypothesis is that microglia, the resident immune cells of the central nervous system, are the major
myeloid cells affected by dysregulated TREM2-DAP12 function. Here, we review how impaired signaling by the
TREM2-DAP12 pathway leads to altered immune responses in phagocytosis, cytokine production, and microglial
proliferation and survival, thus contributing to disease pathogenesis.
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Host survival is dependent on the detection and clear-
ance of diverse virulent pathogens by the innate and
adaptive immune systems. Cells of the myeloid lineage,
including macrophages and dendritic cells (DCs), play a
pivotal role in both sectors of immunity—they are vital
in direct microbe sensing and localized attenuation, and
are also responsible for recruitment of other myeloid
and lympohocyte effector populations. Interestingly, host
receptors normally associated with microbial detection
are also able to respond to acute tissue injury through
recognition of self-derived damage-associated motifs.
How innate immune cells balance the timing and com-
position of their cytokine cocktails is critical for efficient
clearance of pathogen and cellular debris without exces-
sive inflammation and tissue destruction. Genetic associ-
ation studies have demonstrated that dysregulated innate
immune signaling is linked to numerous neurological* Correspondence: Bu.Guojun@mayo.edu
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mutations in the innate immune receptor-adaptor duo,
triggering receptor expressed on myeloid cells 2
(TREM2) and DNAX-activating protein of 12 kDa
(DAP12), have been reported in a spectrum of neurode-
generative disorders including Nasu-Hakola disease
(NHD; or polycystic lipomembranous osteodysplasia
with sclerosing leukoencephalopathy, PLOSL) [8–11],
frontotemporal dementia (FTD) [12–17], Alzheimer’s
disease (AD) [13, 17–23], Parkinson’s disease (PD) [14],
amyotrophic lateral sclerosis (ALS) [24], and essential
tremor [25]. Three non-exclusive hypotheses suggest
roles for TREM2-DAP12 signaling during homeostasis
and how mutations may contribute to altered neuro-
immunological function: (1) TREM2-DAP12 suppresses
inflammatory cytokine production following receptor-
mediated recognition of microbial or self-derived
damage-associated motifs; (2) TREM2-DAP12 mediates
phagocytosis of a variety of microbial and endogenous li-
gands to facilitate debris clearance following injury or in-
sult; and (3) TREM2-DAP12 signaling induces a
transcriptional profile reflective of enhanced myeloid cell
proliferation and reduced cell death. In this Review, we
discuss the historical evidence of the TREM2-DAP12e is distributed under the terms of the Creative Commons Attribution 4.0
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recent data that support a multi-faceted role for micro-
glial TREM2-DAP12 signaling in homeostasis and under
disease challenges in the central nervous system (CNS).
Discovery and validation of TREM2 as a risk gene
for AD and other neurodegenerative diseases
TREM2 belongs to the immunoglobulin (Ig) superfamily
of receptors. It contains an extracellular domain, a trans-
membrane domain, and a short cytoplasmic tail [26].
Oppositely charged intramembrane residues of TREM2
and DAP12 facilitate their interaction [27]. DAP12 is
also a type I transmembrane protein with a cytoplasmic
tail that harbors a single immunoreceptor tyrosine acti-
vation motif (ITAM) [28]. In the periphery, macro-
phages, immature DCs, and osteoclasts are the primary
TREM2-expressing cells in vivo [26, 29–31]. In the CNS,
TREM2 is highly expressed in microglia with approximately
300-fold higher expression compared to neurons and other
glia [32, 33]. DAP12 expression has been reported in cells
of both myeloid and lymphoid origin [28, 31]. Although
DAP12 is able to interact with greater than twenty other re-
ceptors [34], the TREM2-DAP12 axis has received growing
attention due to recent genetic association with neurode-
generative diseases [8–25].
Loss-of-function mutations in both TREM2 and
DAP12 have been reported to cause NHD/PLOSL, an
autosomal recessive disorder in which patients suffer
from systemic bone cysts and progressive encephalop-
athy resulting in presenile dementia [35, 36]. Even
though cases of NHD/PLOSL have been described since
the 1960s, it wasn’t until the late 1990s that inheritance
of the disease was linked to chromosomal region 19q13
[8], and subsequent analysis identified a large chromo-
somal deletion (exons 1–4) of TYROBP, the gene encod-
ing DAP12 [9]. Later, in patients with genetic exclusion
of the 19q13 linkage to disease, it was observed that mu-
tations in TREM2 resulted in an identical NHD/PLOSL
phenotype [10]. Following this discovery, numerous
mutations in TREM2, mostly occurring in exon 2 (IgV
domain), have been linked to other forms of neurode-
generative disease.
FTD encompasses a spectrum of disorders that share
pathological features of frontal and temporal lobe atro-
phy, and depending on the cerebral region most affected,
clinical symptoms can include language deficits and al-
tered behavior [37]. In an effort to identify novel genes
and risk factors associated with disease, patients with an
FTD-like clinical diagnosis underwent whole-exome se-
quencing; the homozygous TREM2 mutations p.Q33X,
p.T66M, and p.Y38C were present in affected individuals
but not in healthy controls [12]. Also, a nonsense
p.W198X mutation [13], and missense p.S116C [16] and
p.R47H [14, 16, 17] mutations have been identified inother FTD cohorts. Similar to the NHD/PLOSL patients
that harbor TREM2 variant alleles, these FTD patients
exhibited characteristic signs of cognitive impairment.
Conversely, they did not show symptoms of bone in-
volvement (e.g., bone cysts). Therefore, it was hypothe-
sized that TREM2 may be a risk allele associated with
other forms of dementia that have not previously been
screened for TREM2 mutations because of their atypical
(non-NHD/PLOSL) clinical presentation [12].
Subsequent studies corroborated this hypothesis, and
in 2013, two seminal papers described TREM2 muta-
tions in AD [18, 19]. In the elderly, AD is the most
common form of dementia with affected individuals
worldwide topping 150 million [38]. Familial, early-
onset AD (EOAD; <65 years) accounts for <1 % of total
cases [39] and are caused by mutations in the APP,
PSEN1, or PSEN2 genes [40–42]. Most AD cases are
referred to as late-onset AD (LOAD; >65 years) with
the greatest genetic risk factor being the ε4 allele of
apolipoprotein E (APOE) [43, 44]. Mutations associated
with both EOAD and LOAD result in toxic amyloid-β
(Aβ) accumulation in the CNS (see below).
In addition to the aforementioned impetus to study
TREM2 in other forms of dementia, a genome search
meta-analysis identified significant evidence for linkage
to LOAD at the 6p21.1-q15 locus (which includes
TREM2) [45]. Therefore, by whole-exome and whole-
genome sequencing of AD patients and unaffected indi-
viduals, Guerreiro et al. [18] and Jonsson et al. [19]
performed genome-wide association analysis with vari-
ants that were predicted to affect protein function. In in-
dependent patient cohorts, both research groups found
that the TREM2 SNP rs75932628-T, encoding the puta-
tive p.R47H variant, conferred a significantly increased
risk of LOAD with odds ratios of 5.05 [18] and 2.92
[19]—which are comparable to that of APOE ε4 [46].
Numerous studies in different ethnic populations have
since confirmed this pivotal finding that the p.R47H vari-
ant of TREM2 is associated with LOAD [13, 17, 20–23].
Furthermore, this SNP has been linked to other neurode-
generative disorders including PD [14], ALS [24], and es-
sential tremor [25].Neuroinflammation in AD
Although overt clinical symptoms of AD do not typically
develop until age 65 years and older, disease-initiating
events most likely begin decades before symptoms of cogni-
tive decline [47]. The pathological features of AD include
amyloid plaques primarily composed of Aβ and neurofibril-
lary tangles (NFTs) that are aggregates of hyperphosphory-
lated microtubule-associated protein tau [48]. The amyloid
cascade hypothesis of AD focuses on the process of Aβ ac-
cumulation and aggregation, which trigger a wave of
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and neuronal degeneration [39].
Aβ peptides, which are typically 39–43 amino acids
in length, are derived from sequential cleavage of
amyloid precursor protein (APP) by β- and γ-
secretases [49]. During homeostasis, Aβ is continu-
ously generated and removed from brain tissue.
However, under pathogenic conditions when Aβ pro-
duction is elevated or Aβ clearance is impaired, this
imbalance leads to accumulation and subsequent for-
mation of toxic oligomers, fibrils, and plaques. Mu-
tations found in patients with familial EOAD—APP,
or PSEN1 and PSEN2, components of the γ-secretase
complex—result in overproduction of amyloidogenic
Aβ [50]. Evidence supports impaired Aβ clearance as
a major contributing pathway for LOAD [51]. A uni-
fying theme is that Aβ aggregates trigger excessive
immune responses which can be harmful to synapses
and neurons and further impair Aβ clearance.
Aβ aggregates can activate classical innate immune
microbial receptors [48]. For example, during a bac-
terial infection, the host’s pattern recognition recep-
tor (PRR), toll-like receptor 4 (TLR4), is able to
detect bacterial lipopolysaccharide (LPS) as a foreign
pathogen-associated molecular pattern (PAMP). In
turn, pro-inflammatory pathways are activated which
aid in the recruitment of additional myeloid and
lymphoid effector populations. It is speculated that
through an evolutionarily-conserved mechanism to
sense and respond to acute tissue injury, host PRRs
are also able to recognize self-derived damage-
associated molecular patterns (DAMPs). In this way,
aggregated Aβ, acting as a DAMP, can activate pro-
inflammatory cytokine production through host PRRs
[52], including TLR4 [53]. During infection, such sen-
sor activation induces local inflammation followed by
resolution to baseline once pathogen attenuation has
occurred. Conversely, accumulation of toxic amyloid
causes constitutive PRR-mediated Aβ detection that in-
duces chronic stimulation of the innate immune sys-
tem [38].
Recently, genome-wide association studies (GWAS)
have confirmed an active role for innate immune cells
in the regulation of the inflammatory milieu within the
CNS. In addition to TREM2, mutations in the myeloid
receptor CD33 (also known as Siglec-3) [5–7], comple-
ment receptor 1 (CR1) [1], and myeloid cell-expressed
membrane-spanning 4-domains subfamily A member
6A (MS4A6A) and MS4A4E [6, 7] have been shown to
increase the risk of developing AD. These findings sup-
port the hypothesis that aberrant activation or im-
paired function of the innate immune system
contributes to the initiation and propagation of the
inflammatory process leading to AD.TREM2-DAP12 axis inhibits TLR-induced
inflammation
In the CNS, microglia provide protective surveillance for
parenchymal cells from both intrinsic and extrinsic in-
sults. As the primary cellular innate immune compo-
nent, microglia act as the major PAMP/DAMP detectors
and are equipped with an assortment of cytosolic, endo-
somal and plasma-membrane-bound PRRs, including all
of the TLR subtypes [54]. Delineating key events in
TLR4-mediated induction of pro-inflammatory cytokines
has become a major focus of AD research since amyloi-
dogenic proteins have been shown to activate canonical
pathogen-associated signal transduction cascades via
TLR4 ligation [55–57]. PAMP/DAMP engagement of
TLR4 (in complex with MD2 and facilitated by CD14
and LBP) recruits the TIR domain-containing adaptor
molecules (including MyD88 and TRIF) which activate
NF-κB and mitogen-activated protein kinases (including
ERK, JNK, and p38) to induce production of inflamma-
tory cytokines [58].
Similar to TLR4, TREM2 has been described as both a
PAMP [59, 60] and a DAMP [61–64] sensor; TREM2 is
capable of binding gram-positive and gram-negative bac-
teria [59, 60] as well as a number of ligands exposed
during CNS degeneration including anionic, zwitter-
ionic, and myelin-associated lipids [61, 62], and nucleic
acid released from dying cells [64]. Due to overlap in
stimulatory ligands, it has been difficult to delineate sig-
nals emanating from each receptor pathway; however,
TREM2 depletion experiments in combination with
TLR4-LPS stimulation have begun to define the exact
role each receptor plays in the neuroinflammatory
response.
In order to characterize whether TREM2-DAP12 sig-
naling is able to modulate TLR4-mediated inflammatory
cytokine production, Turnbull and colleagues generated
Trem2−/− mice [30]. Wild-type (WT) and Trem2−/−
bone-marrow-derived macrophages (BMDMs) and pri-
mary peritoneal macrophages were stimulated with LPS
and cytokine levels were assayed. In both macrophage pop-
ulations, pro-inflammatory TNF-α and IL-6 were signifi-
cantly increased in the absence of TREM2 [30]. Following
LPS stimulation, synthesis of pro-inflammatory cytokines
were similarly elevated in TREM2-depleted microglia and
DCs [62, 63, 65], and in DAP12-deficient BMDMs [66].
More recently, knockdown of either TREM2 or DAP12 in
the microglial cell line BV2 significantly increased IL-1β
and IL-6 following LPS stimulation. Importantly, overex-
pression of full-length TREM2 or the DAP12-interacting
C-terminal fragment (CTF) of TREM2 were able to sup-
press excessive pro-inflammatory cytokine production [67].
In an effort to investigate the molecular mechanism by
whichTREM2-DAP12 attenuates TLR4-mediated signaling,
Peng and colleagues stimulated BMDMs from WT mice
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with an anti-DAP12 antibody [68]. They found that the
adaptor protein Dok3 was associated with the ITAM
motif of DAP12 via the phosphotyrosine-binding do-
main. In a Src-dependent but Syk-independent manner,
phosphorylated-Dok3 translocated from the cytoplasm
to the plasma membrane where it associated with Grb2
and Sos1 which prevented activation of the RAS-ERK
pathway (Fig. 1) [68]. Therefore, Dok3 participates in
DAP12-mediated inhibition of TLR4-induced secretion
of pro-inflammatory cytokines by blocking the ERK
pathway. These results provide mechanistic insight into
previous observation that Dap12−/− BMDMs exhibitFig. 1 The TREM2-DAP12 axis modulates homeostatic functions via crosstalk w
expressed within microglia [32, 33]. Although signaling events need to be sequ
genetic depletion experiments in vitro support a multi-faceted role for TREM2-D
production following PRR-mediated recognition of PAMPs/DAMPs. LPS stimu
recruited to the plasma membrane. There, pDok3 binds Grb2 and Sos1, thus
production of pro-inflammatory cytokines [68]. Similar to full-length TREM
anti-inflammatory effects [67]. TREM2-DAP12 facilitates phagocytosis of PA
insult. Src kinase phosphorylation of the tyrosine residues of the DAP12 ITAM
guanine nucleotide exchange factors Vav2/3 [74, 75] which are capable of act
cytoskeleton [60]. TREM2-DAP12 signaling synergizes with that of CSF-1R to indu
and reduced cell death. CSF-1 via CSF-1R induces phosphorylation of DAP12 b
by DAP12-dependent phosphorylation of Syk and subsequent Pyk2-depe
[80, 81]increased phosphorylated ERK in response to LPS
stimulation [66].
Experiments using TLR DAMPs further support the
hypothesis that TREM2-DAP12 is able to modulate pro-
inflammatory signaling. In microglia, TREM2 or DAP12
knockdown led to significant increases in TNF-α, IL-1β,
and IL-6 when incubated with apoptotic neurons [63] or
Aβ [69]. However, contrary to these results, Jay et al. re-
cently reported that in a mouse model of AD, TREM2
deficiency actually reduced pro-inflammatory cytokine
levels (IL-1β and IL-6) in brains of APPPS1-Trem2−/−
mice [70]. One potential explanation for this discrep-
ancy, the authors contend, is that the CNS-infiltratingith diverse signaling pathways. In the CNS, TREM2-DAP12 is preferentially
entially validated in microglia that endogenously express TREM2-DAP12,
AP12 in CNS homeostasis; TREM2-DAP12 suppresses inflammatory cytokine
lation induces DAP12-dependent phosphorylation of Dok3 which is then
preventing the activation of RAS and ERK, as well as the subsequent
2, expression of only the TREM2-CTF leads to DAP12-dependent
MPs/DAMPs and promotes cellular debris clearance following injury or
domain creates a docking site for Syk and downstream activation of the
ivating Rac1/Cdc42-dependent phagocytosis and regulation of the actin
ce a transcriptional profile reflective of enhanced myeloid cell proliferation
y Src kinases associated with tyrosine residue 559 of the CSF-1R, followed
ndent activation of β-catenin-regulated pro-survival pathways
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dent microglia, is the key TREM2-expressing myeloid ef-
fector in AD pathogenesis [70]. Another explanation
could be the timing in which inflammation was
assessed—in vitro, inflammatory markers were assayed
within hours to days of PAMP/DAMP stimulation [62,
63, 30, 65–69]; in vivo, the neuroinflammatory environ-
ment was assayed under conditions of constitutive PRR
activation in brain lysates of four-month old mice [70].
In support of temporal cytokine fluctuations related to
TREM2 signaling, a recent study measured IL-6 levels in
peritoneal lavage fluid from WT and Trem2−/− mice 6
and 20 h after LPS injection [71]. At 6 h, Trem2−/− mice
exhibited robustly increased IL-6 compared with con-
trols. However, rapid resolution of the inflammatory re-
sponse was observed in Trem2−/− mice, leading to
significantly decreased IL-6 levels at 20 h. Interestingly,
when mice were challenged with E. coli in a pathogenic
peritonitis model, at 16 h post-infection Trem2−/− mice
still maintained higher IL-6 levels in blood plasma com-
pared with controls; yet, there was no statistically-
significant survival advantage in either group. Since
inflammation did not correlate with survival outcome,
the authors suggested that TREM2 might concurrently
affect the antimicrobial effector mechanism of bacterial
phagocytosis, which was reduced both in vitro and
in vivo in Trem2−/− mice [71].
Overall, TREM2-DAP12 signaling likely modulates
pro-inflammatory signals originating from TLR4 via
intracellular DAP12-Dok3 pathway [68]. Additionally, as
alluded to above, it is possible that production of TLR4-
induced inflammatory cytokines could be blunted via in-
direct mechanisms; TREM2-mediated phagocytosis of
pathogenic PAMPs and/or amyloidogenic DAMPs would
deplete the pool of extracellular stimulatory ligands that,
in excess, activate PRR-mediated production of pro-
inflammatory cytokines.
TREM2-DAP12 signaling facilitates phagocytosis
Shortly after the discoveries that linked genetic variants
of DAP12 [9] and TREM2 [10] to the neurodegenerative
disease NHD/PLOSL, Takahashi et al. sought out to in-
vestigate the role of TREM2-DAP12 within the CNS
[63]. Specifically, they analyzed the vital microglial func-
tion of clearing apoptotic cells with or without intact
TREM2 signaling. TREM2-shRNA or overexpression
lentiviral vectors were used to transduce primary mouse
microglia and then phagocytosis of apoptotic neurons
was assayed in vitro. When TREM2 was knocked down,
significantly fewer microglia phagocytosed apoptotic
neuronal membranes compared with controls. Interest-
ingly, when TREM2 was overexpressed the percentage
of microglia that phagocytosed apoptotic neurons was
increased which validated the role of TREM2 inphagocytosis [63]. Other experiments in vitro have
yielded similar results; TREM2- or DAP12-deficient
microglia incubated with Aβ [69, 72], Trem2−/− peri-
toneal macrophages or microglia incubated with E. coli
[71, 72], and TREM2-depleted BV2 microglia incubated
with apoptotic Neuro2A cells [73] showed a signifi-
cantly attenuated capacity to phagocytose various
PAMPs/DAMPs.
Importantly, N’Diaye et al. unequivocally demon-
strated that TREM2-DAP12 expression is sufficient to
facilitate phagocytosis in vitro [60]. Authors used the
Chinese hamster ovary cell line that was transfected with
a TREM2-DAP12 fusion construct and incubated with E.
coli. Although these cells are typically considered to be
non-phagocytic, they rapidly internalized bacteria in a
TREM2-DAP12-dependent manner. Furthermore, this
mechanism required Src kinase activity, tyrosine phos-
phorylation of the DAP12 ITAM domain, Syk, and the
small guanosine triphosphates Rac1 and Cdc42 [60]. The
Vav guanine nucleotide exchange factor family may also
be a critical link in this TREM2-DAP12 signaling axis;
Vav2 and Vav3 are mediators of DAP12-ITAM signals
[74] and are capable of activating Rho-Rac/Cdc42 [75].
Although events need to be sequentially validated in
myeloid cells that express endogenous TREM2, it is
tempting to speculate that TREM2-DAP12 mediated
phagocytosis can occur via Src-Syk-Vav2/3-Rac1/Cdc42-
Arp2/3 (Fig. 1). Additional support for this model can
be extrapolated from network analysis of critical
TREM2-dependent signaling cascades in the human brain
with significant enrichment for microglial-mediated cyto-
skeletal rearrangements necessary for phagocytosis—also
highlighted within this network is the high degree of inter-
connectedness among TREM2, Vav, and Arp2/3 [76].
Data from in vivo experiments mirror in vitro findings
and similarly support the ability of TREM2 to facilitate
phagocytosis. In cell culture, when BMDMs were trans-
duced with a TREM2-overexpression vector, phagocyt-
osis of microsphere beads and apoptotic neurons was
significantly increased [77]. In order to investigate
whether this increased expression of TREM2 in periph-
eral myeloid cells could alter disease course in mice
afflicted with the experimental autoimmune encephalo-
myelitis model of multiple sclerosis, myeloid cells were
intravenously injected and cellular homing, myelin deb-
ris clearance, and disease progression were monitored.
TREM2-transduced myeloid cells migrated to CNS le-
sions, facilitated myelin debris clearance and ameliorated
clinical symptoms of disease. Intrigued by these findings,
the authors suggested that TREM2 is an attractive target
for promoting CNS repair in neuroinflammatory dis-
eases [77]. Consistent with this hypothesis, TREM2
knockdown in BV2 microglia attenuated phagocytosis of
oxygen-glucose-deprived neurons in vitro, and likewise
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mic brain parenchyma in an experimental stroke model.
Specifically, oil red O-positive staining was used to iden-
tify phagocytosed intracellular lipids within CNS tissue;
approximately 50 positive cells per field were counted in
WT ischemic mouse brains compared with <1 positive
cell per field in Trem2−/− mice. Importantly, brain in-
farct size was larger (less infarcted brain resorption) in
Trem2−/− mice which correlated with increased severity
of neurological deficits [64].
Additionally, postmortem analyses of brain tissue from
NHD/PLOSL patients revealed demyelinating lesions
within the subcortical white matter [78]. In order to in-
vestigate how loss of TREM2 contributes to the patho-
genesis of white matter tracts, cuprizone-induced
nonautoimmune demyelination was assessed in vivo
[61]. The cuprizone model is characterized by apoptosis
of mature oligodendrocytes and activation of brain-
resident microglia that remove damaged myelin. WT
and Trem2−/− mice were fed a cuprizone-containing diet
for twelve weeks and then fed a cuprizone-free diet for
two weeks and myelination was assessed by transmission
electron microscopy. In WT mice, the corpus callosum
contained remyelinated white matter tracks following
the recovery phase. Conversely, corpus callosum in
Trem2−/− mice was largely demyelinated with visible de-
position of myelin debris and axonal swelling. In vitro,
purified lipid components such as sulfatide, sphingomye-
lin, and various phospholipids were capable of stimulat-
ing TREM2 signaling. Therefore, the authors proposed
that microglia require TREM2 for myelin debris removal
in a process that depends on TREM2 detection of lipid
components exposed during myelin injury [61]. Contrary
to these results, a recent paper presented evidence that
TREM2 does not directly facilitate phagocytosis. Instead,
it was proposed, TREM2 promotes microglial survival by
synergizing with colony stimulating factor-1 receptor
(CSF-1R) signaling [62].
TREM2-DAP12 signaling promotes myeloid cell
survival
Wang and colleagues observed that when Trem2−/−
mice were crossed to an AD mouse model, TREM2
deficiency neither had impact on microglial uptake of
Aβ aggregates nor intracellular proteolytic processing
of Aβ [62]. However, in brain sections from 5XFAD-
Trem2−/− mice there were more TUNEL-positive micro-
glia compared with TREM2-expressing 5XFAD con-
trols. Cell culture experiments using primary microglia
expanded in conditioned media with colony-stimulating
factor (CSF-1), which mimics the in vivo microenviron-
ment [79], demonstrated that glia from 5XFAD-Trem2
−/− mice were significantly less viable than controls [62].
Earlier work by the same group provided valuablemechanistic insight—a CSF-1R-DAP12-β-catenin sig-
naling network regulates survival and proliferation of
myeloid cells [80]. In vitro, they showed that DAP12-
deficient BMDMs had significantly impaired growth
compared to WT cells when cultured for seven days
with CSF-1. Specifically, a smaller percentage of
DAP12-deficient BMDMs were in S and G2 phases
compared with WT BMDMs [80]. Interestingly,
retroviral-mediated DAP12 reconstitution restored cell-
cycle profiles to approximately WT levels demonstrat-
ing that DAP12 is required for CSF-1-induced BMDM
proliferation. Analysis of the molecular mechanism fur-
ther revealed that CSF-1 via CSF-1R induces phosphor-
ylation of DAP12 by Src kinases associated with
tyrosine residue 559 of the CSF-1R, followed by DAP12-
dependent phosphorylation of Syk and subsequent
Pyk2-dependent activation of β-catenin (Fig. 1) [80, 81].
In this way, CSF-1 promotes proliferation and survival
of myeloid cells via a DAP12-β-catenin-dependent
pathway [80].
TREM2-DAP12-dependent signaling also prevents
myeloid cell apoptosis during respiratory viral infection,
albeit by a different molecular mechanism [82]. Cleav-
age of cell surface TREM2 to soluble TREM2 (sTREM2)
has classically been speculated to result in formation of
an inactive end product. However, Wu et al. recently
presented data that counter conventional thought. The
authors found that an increase in sTREM2 levels posi-
tively correlated with IL-13 production in diseased lung
tissue and that exogenous administration of IL-13 (or
IL-4 using the same receptor component) resulted in a
time-dependent increase in sTREM2 released from
BMDMs. Importantly, BMDMs treated with recombin-
ant sTREM2 (amino acids 19–136) showed reduced
cleaved caspase-3 and were spared from apoptosis (in-
duced by CSF-1 withdrawal). This protective effect oc-
curred in a sTREM2 dose-dependent manner, was
irrespective of BMDM genotype (WT, Trem2−/−, or
Dap12−/−), and was due to attenuated apoptotic signal-
ing instead of cellular proliferation since BrdU incorpor-
ation was unaffected by sTREM2 treatment. The
authors concluded that sTREM2 is unexpectedly active
and capable of promoting macrophage survival [82].
Data that further support a neuroprotective role for
sTREM2 is derived from analysis of cerebrospinal fluid
samples from AD and FTD patients which shows sig-
nificantly decreased levels of sTREM2 compared to
healthy controls [72].
Since differentially cleaved forms of TREM2 are bio-
logically active (including the plasma-membrane-bound
TREM2-CTF [67] and the sTREM2 ectodomain [82]),
insight into how TREM2 is transported to the cell surface
and processed is necessary. Understanding the lifecycle of
this receptor will determine whether, and how, these
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neurodegenerative disease.
TREM2 mutations linked to neurodegenerative
disease—loss of function or gain of toxic
function?
Most likely through glycosylation, membrane-bound
TREM2 matures from a low-molecular weight immature
form to a higher-molecular weight form ranging be-
tween 36 and 60 kDa. Once mature, TREM2 is shed
from the membrane as 36–50 kDa sTREM2 by a disin-
tegrin and metalloproteinase domain-containing pro-
tein, ADAM10 [72]. The membrane-bound CTF stub
can still associate with and signal through DAP12 [67],
but this fragment can also serve as a substrate for
intramembrane-mediated γ-secretase cleavage [83]
yielding an intracellular domain (ICD) with unknown
function. Unlike non-mutated TREM2, expression of
the TREM2 variants p.T66M and p.Y38C (associated
with genetic risk of FTD [12, 16]) in HEK293 or BV2
microglial cells, led to accumulation of immature,
membrane-bound TREM2 species (~36 kDa). Consist-
ent with reduced maturation, p.T66M and p.Y38C
mutants exhibited significantly diminished ADAM10-
mediated proteolytic cleavage as evidenced by both de-
creased levels of sTREM2 and membrane-bound CTF
[72]. The p.R47H mutant (associated with genetic risk
of AD [13, 17–23], PD [14], ALS [24], and essential
tremor [25]) showed slightly less, albeit similar patterns
of cell-surface TREM2 expression, maturation, and
sTREM2 generation compared with non-mutated
TREM2 [72]. In order to assess the functional outcome
of reduced mature, cell-surface TREM2 expression by
the genetic mutants, a number of assays were used to
investigate their phagocytic capacity. Interestingly,
p.T66M and p.Y38C mutations significantly inhibited
TREM2’s ability to mediate phagocytosis of latex beads,
E. coli, and Aβ peptide. When the TREM2-R47H mu-
tant was correspondingly used in assays, a decreased
ability to phagocytose latex beads and Aβ peptide com-
pared with TREM2 was observed. However, this effect
was less pronounced in the p.R47H mutant compared
with the other TREM2 variants, and p.R47H did not
affect TREM2’s ability to mediate phagocytosis of E.
coli [72]. In regards to TREM2-R47H, it appears that
the largest effect was reduced levels of total TREM2
protein when transiently or stably expressed in vitro
[72]. Therefore, it is possible that moderate effects on
maturation and phagocytic capacity were solely driven
by reduced TREM2 protein expression compared to
control. Thus, in this context it is difficult to assess the
functional nature of the p.R47H mutation.
Recently, another study investigated the biological ef-
fect of TREM2-R47H [62]. As previously discussed,Wang et al. found that TREM2 does not directly medi-
ate phagocytosis, instead TREM2’s function in the CNS
is two-fold—TREM2 is a sensor that detects lipids that
are exposed during conditions of brain injury/insult and
TREM2 promotes microglial survival via CSF-1R signal-
ing [62]. Using the p.R47H variant, the authors reported
that TREM2 cell-surface expression was unaffected by
mutation. However, they found that the p.R47H muta-
tion significantly reduced the ability of TREM2 to bind
damage-associated lipids [62].
Overall, the p.T66M and p.Y38C mutations appear to
alter trafficking and processing of TREM2 and impair
TREM2-mediated phagocytosis of various ligands [72].
This effect of impaired phagocytic capacity mirrors
in vitro findings using TREM2-deficient cell lines [63,
69, 71–73]. Therefore, these data support the hypothesis
that TREM2 p.T66M and p.Y38C mutations exert loss-
of-phagocytic function. However, results from p.R47H
experiments are seemingly more ambiguous. If the
p.R47H mutation encodes a TREM2 receptor that is
unable to interact with microbial PAMPs and/or en-
dogenous DAMPs, this would result in significant loss-
of-biological function on multiple levels. Unlike TREM2
that supports receptor-ligand interaction, TREM2-R47H
may have impaired ability to bind ligands that modulate
homeostatic functions. However, it is also possible that
the p.R47H mutation encodes a TREM2 receptor that
no longer interacts with PAMPs/DAMPs and instead ec-
topically engages a novel ligand(s). Therefore, depending
on the quantitative or temporal frequency at which this
novel epitope is expressed, receptor-ligand interaction
might result in aberrant signaling leading to a toxic-
gain-of function. Similarly, TREM2-R47H may act as a
decoy receptor by binding to a novel ligand and inhibit-
ing engagement with its cognate receptor. In this way,
TREM2-R47H could deplete the exogenous pool of a
critical growth factor or survival signal, for example. To
date, the biological consequence of mutations linked to
neurodegenerative disease have only been evaluated in
the context of TREM2 receptor trafficking and process-
ing [72], phagocytosis [72], and DAMP sensing [62].
However, whether mutant TREM2-expressing microglia
affect the inflammatory milieu of their CNS microenvir-
onment or whether they participate in cell survival sig-
naling has yet to be evaluated in vitro or in vivo.
Conclusion
Microglia are an essential cadre of innate immune cells
within the brain parenchyma entrusted with CNS
defense against invading pathogens and the orchestra-
tion of tissue repair and regeneration following injury.
Microglia are able to propagate diverse receptor signals
and translate them into cell-type specific instructions for
neurons and other glia through a delicate balance of
Painter et al. Molecular Neurodegeneration  (2015) 10:43 Page 8 of 10pro- and anti-inflammatory paracrine signals. Therefore,
it is understandable that mutations in receptors prefer-
entially expressed on microglia within the CNS have
been shown to increase the risk of developing neuro-
logical diseases [10–25, 1, 5–7]. TREM2 is a premier ex-
ample of how mutations in a microglial receptor can
lead to aberrant innate immune cell signaling that con-
tributes to the initiation and propagation of neurodegen-
erative phenotypes including NHD/PLOSL [10, 11], FTD
[12–17], AD [13, 17–23], PD [14], ALS [24], and essen-
tial tremor [25].
TREM2 and DAP12 genetic depletion studies in vitro
and in vivo support three main roles for TREM2-DAP12
signaling (Fig. 1): (1) TREM2-DAP12 suppresses inflam-
matory cytokine production following PRR-mediated
recognition of PAMPs/DAMPs; (2) TREM2-DAP12 fa-
cilitates phagocytosis of PAMPs/DAMPs and promotes
cellular debris clearance following injury or insult; and
(3) TREM2-DAP12 signaling induces a transcriptional
profile reflective of enhanced myeloid cell proliferation
and reduced cell death.
To date, numerous studies have investigated the gen-
etic link between TREM2 variants and neurodegenera-
tive diseases [10–25]; however only two studies have
empirically tested the functional outcome of these muta-
tions [62, 72]. TREM2 p.T66M and p.Y38C mutations
appear to alter trafficking and processing of TREM2 and
impair TREM2-mediated phagocytosis of numerous li-
gands [72] which supports the hypothesis that p.T66M
and p.Y38C mutations exert loss-of-biological function,
at least in the context of phagocytosis. If this indeed is
the case, then TREM2-deficient cell lines and mice
would serve as ideal platforms to test how loss of
TREM2 impacts pathogenesis under conditions that
simulate neurodegenerative disease.
Conversely, the biological significance of the p.R47H
mutation is less clear. Wang et al. contend that the
p.R47H mutation encodes a TREM2 receptor that is un-
able to interact with endogenous ligands [62]. Since
TREM2 inhibits pro-inflammatory cytokine production,
facilitates phagocytosis, and promotes cell survival, this
finding could imply a significant loss of homeostatic
function. However, it is also possible that TREM2-R47H
is able to ectopically engage different epitopes and may
therefore assume novel roles via aberrant signaling or se-
questration of critical ligands. What is clear is that fu-
ture work must focus on understanding the functional
outcome of the p.R47H mutation given its genetic link
to numerous neurodegenerative diseases [13, 14, 17–25].
In vitro and in vivo experiments utilizing TREM2-R47H-
overexpression constructs should first determine how
microglia expressing this variant are able to interact with
other cells within their CNS microenvironment during
homeostasis and normal aging. Once this relationshiphas been established, subsequent experiments should in-
vestigate the phenotype of TREM2-R47H-expressing
microglia under conditions that mimic early steps in the
neurodegenerative disease process (e.g., Aβ accumula-
tion and amyloid plaque deposition in AD).
Lastly, it is important to consider, and empirically deter-
mine, whether the biological outcome of TREM2 muta-
tion is, in fact, due to full-length, cell-surface, membrane-
bound TREM2 receptor signaling, or whether detrimental
effects may be mediated via altered production of other
biologically-active TREM2 cleavage products, such as
sTREM2, TREM2-CTF, or TREM2-ICD.
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